Q4 2025 Management View Brian Lian, President and CEO, highlighted several milestones in 2025, focusing on the obesity pipeline: "With the subcutaneous formulation of our lead molecule, VK2735, ...
GLP-1 market growth is fueling Viking Therapeutics‘ (VKTX) momentum with VK2735 in Phase 3 and VK2809’s NASH success. Viking is advancing dual therapies amid a $150 billion obesity opportunity. With a ...
Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results